Which diabetic medication is known to increase insulin production?

Which diabetic medication is known to increase insulin production?

• A. Sulfonylurea
• B. Biguanides
• C. GLP-1 agonists
• D. DPP-4 inhibitors

Answer: (A)

Sulfonylureas are a class of medications that stimulate the pancreas to produce more insulin in response to glucose levels. They work by binding to specific receptors on the pancreatic beta cells, promoting insulin secretion. This mechanism is particularly beneficial for individuals with type 2 diabetes who have some residual pancreatic function. In contrast, biguanides, such as metformin, primarily work by decreasing hepatic glucose production and improving insulin sensitivity rather than directly stimulating insulin secretion. GLP-1 agonists also stimulate insulin secretion, but their mechanism includes enhancing glucose-dependent insulin secretion and slowing gastric emptying, rather than exclusively increasing insulin production. DPP-4 inhibitors, on the other hand, increase endogenous incretin levels, which leads to enhanced insulin secretion, but they do not directly increase insulin production in the same way that sulfonylureas do. Overall, the action of sulfonylureas specifically targets and increases insulin production, making this the correct answer in the context of the question.

Sulfonylureas are a class of medications that stimulate the pancreas to produce more insulin in response to glucose levels. They work by binding to specific receptors on the pancreatic beta cells, promoting insulin secretion. This mechanism is particularly beneficial for individuals with type 2 diabetes who have some residual pancreatic function.

In contrast, biguanides, such as metformin, primarily work by decreasing hepatic glucose production and improving insulin sensitivity rather than directly stimulating insulin secretion. GLP-1 agonists also stimulate insulin secretion, but their mechanism includes enhancing glucose-dependent insulin secretion and slowing gastric emptying, rather than exclusively increasing insulin production. DPP-4 inhibitors, on the other hand, increase endogenous incretin levels, which leads to enhanced insulin secretion, but they do not directly increase insulin production in the same way that sulfonylureas do.

Overall, the action of sulfonylureas specifically targets and increases insulin production, making this the correct answer in the context of the question.